When New Zealand dog owners encounter the NexGard product range for the first time, a common source of confusion is the relationship between NexGard and NexGard Spectra. Both are monthly oral chewables for dogs from the same manufacturer. Both are recommended by vets. Both are available as NexGard flea treatment NZ authorised retailers supply. But they are distinct products with meaningfully different coverage profiles, and choosing between them based on your dog’s specific needs and location makes a real difference to the protection your dog receives.
NexGard: Flea and Tick Specialist
Standard NexGard is a monthly oral chewable containing afoxolaner as its sole active ingredient. It provides flea and tick protection through the disruption of GABA-gated chloride channels in invertebrate nervous systems – the same isoxazoline mechanism that makes Bravecto effective. NexGard kills fleas within four hours of dosing and achieves greater than ninety-nine percent flea elimination within twenty-four hours. Tick efficacy varies by species but is generally within twenty-four to forty-eight hours.
NexGard is the appropriate choice when the primary requirement is flea and tick control, and internal parasite management is handled separately with a dedicated worming product. For dog owners who prefer to use specific products for each category of parasite – knowing exactly what each product covers and when each dose is due – standard NexGard provides the flea and tick component without combination with internal parasiticides.
NexGard Spectra: The Comprehensive Option
NexGard Spectra adds milbemycin oxime to the afoxolaner base. This addition extends coverage to heartworm prevention, roundworm, hookworm, and whipworm – addressing both external and internal parasites in a single monthly chew. The flea and tick efficacy of NexGard Spectra is identical to standard NexGard; the milbemycin oxime addition affects internal parasites only. For dog owners who want one product covering the full range of significant parasite threats, NexGard Spectra eliminates the need for a separate worming product.
For New Zealand dogs in heartworm risk areas – Auckland, Northland, and the Waikato – NexGard Spectra is the stronger choice unless the dog is already on a separate heartworm prevention product. The heartworm component is the most medically significant differentiator between the two products; the intestinal worm coverage, while valuable, addresses parasites that are easily detected and less likely to cause serious disease if treated when identified.
Heartworm Risk: The Critical NZ Consideration
Heartworm (Dirofilaria immitis) is transmitted by mosquitoes and causes progressive, potentially fatal cardiovascular disease in dogs. In New Zealand, it has been confirmed in the northern North Island where conditions support the mosquito vectors responsible for transmission. Prevention requires consistent monthly dosing – milbemycin oxime works by eliminating larvae before they can develop into adult worms, and this window of susceptibility requires the drug to be present monthly.
This makes the consistency requirement for NexGard Spectra more critical than for products that only cover external parasites. Missing a month of flea treatment results in a period of flea vulnerability that can usually be addressed quickly. Missing a month of heartworm prevention in a risk area may create a window during which larvae establish and begin developing toward adult worms – a problem that cannot simply be resolved by resuming prevention.
What Neither Product Covers: Tapeworms
Neither standard NexGard nor NexGard Spectra covers tapeworms. Dogs that hunt or that have ongoing flea exposure – since fleas transmit Dipylidium caninum through the grooming-ingestion route – may require periodic additional tapeworm treatment containing praziquantel. For most New Zealand dogs, this is an annual or bi-annual addition to the routine rather than a monthly requirement, but it is worth discussing with your veterinarian for dogs with significant hunting behaviour or persistent flea exposure.
Making the Choice for Your Dog
The decision between NexGard and NexGard Spectra is primarily driven by heartworm risk. In heartworm risk regions of New Zealand without separate heartworm prevention, NexGard Spectra is the appropriate choice. In lower-risk areas, or for dogs already on separate heartworm prevention, standard NexGard provides effective flea and tick control at a modest cost difference.
Both products are beef-flavoured soft chewables with high palatability and essentially identical administration. Both are prescription-only and available from authorised pet supply NZ retailers. The choice should be guided by where you live and what your dog’s specific risk profile requires.
The Practical Decision for Most NZ Dog Owners
For most New Zealand dog owners outside the heartworm risk regions, the choice between NexGard and NexGard Spectra comes down to whether you want internal parasite coverage included in your flea treatment product. NexGard Spectra provides it; standard NexGard does not. The cost difference is modest relative to the convenience of having everything in one product. For most owners, NexGard Spectra represents better value when all the coverage components are considered.
For dogs in Auckland, Northland, or the Waikato where heartworm is a genuine risk, NexGard Spectra is the clear choice unless a separate heartworm prevention product is already in use. The monthly milbemycin oxime component provides reliable heartworm prevention that protects against a disease that is entirely preventable but serious once established. Both products are available from authorised
pet supply NZ
retailers with a current veterinary prescription.
Getting the Right Product for Your New Zealand Pet
New Zealand pet owners have access to a well-regulated market of veterinary parasite prevention products that has improved significantly in both breadth and accessibility over the past decade. The combination of prescription-only status for the most effective treatments – ensuring veterinary oversight – and the growth of authorised online retailers – ensuring competitive pricing – means that effective, consistent parasite prevention is both medically supported and economically accessible.
The practical framework for most New Zealand pet owners is straightforward: establish the appropriate product for your specific animal at the annual veterinary check-up, obtain the prescription, and source the year’s supply from an authorised pet supply NZ retailer. Maintain the schedule consistently using whatever reminder system works reliably for your household, treat all animals in the household simultaneously, and include environmental management when addressing any existing infestation. This approach provides the best possible parasite protection for your pet without unnecessary complexity or cost.
When to Review Your Current Approach
Parasite management should be reviewed at any annual veterinary check-up, any time a pet changes weight significantly enough to affect its weight-range formulation, any time a new pet joins the household and requires integration into the existing programme, and any time a product appears to be failing – whether through apparent treatment failure, unexpected adverse effects, or a change in the pet’s health circumstances that might create new product considerations.
The New Zealand veterinary profession is well-informed about local parasite prevalence, regional heartworm risk, and the evidence base for current product recommendations. Your local vet’s advice is more specifically relevant to your area and your individual animal than any general information source – including this one. Use annual check-ups as the opportunity to validate that your current approach remains appropriate, and use authorised pet supply NZ retailers for cost-efficient routine supply between those annual reviews.
